A Study of Suizenji in Patients With Unresectable Pancreatic Cancer
The purpose of this study is to evaluate the safety and efficacy of standard chemotherapy with or without a novel High Intensity Focused Ultrasound system (Code: Suizenji) in patients with unresectable pancreatic cancer who are refractory or intolerant to first-line chemotherapy.
Unresectable Pancreatic Cancer
DEVICE: Suizenji|DRUG: Nal-IRI/FL|DRUG: mFOLFIRINOX|DRUG: Gem/nab-PTX
Overall Survival, Up to approximately 24 months
Progression-free survival, Up to approximately 12 months|1-year survival rate, Up to approximately 12 months|Objective response rate, Up to approximately 12 months|Disease control rate, Up to approximately 12 months|Adverse Events, Up to approximately 12 months
The purpose of this study is to evaluate the safety and efficacy of standard chemotherapy with or without a novel High Intensity Focused Ultrasound system (Code: Suizenji) in patients with unresectable pancreatic cancer who are refractory or intolerant to first-line chemotherapy.